Chairwoman, Board of Directors
Dr. Maria Rieders joined the Board of Directors of NMS Labs in 2013. She holds an adjunct full professor position at the Wharton School at the University of Pennsylvania where she teaches courses on stochastic processes, queueing theory and operations management. Dr. Maria Rieders holds a M.Sc. degree in applied mathematics from the Universitat Ulm, Germany and a Ph.D. in business administration from the University of Rochester. Previous employments include a scientific staff position at the Allensbach Institute for Public Opinion Research in Allensbach, Germany, a faculty position at the Department of Industrial Engineering and Management Sciences at Northwestern University, and a visiting researcher post at the Institute for Operations Research at the Universität Bonn, Germany. Her research focuses on designing and analyzing stochastic models and has been funded by the National Science Foundation, by Ameritech Corporation, and, through collaboration with students, by Motorola and Argonne National Laboratory.
Michael F. Rieders
Treasurer and Director, Board of Directors
Dr. M. Fredric Rieders, Treasurer and a Director at NMS Labs in Horsham, Pennsylvania.
NMS Labs, Inc. is a US and internationally (ISO) accredited private, independent clinical diagnostic toxicology and forensic science laboratory serving justice, patient care and public health since 1970. Dr. Rieders was CEO from 1988 – 2008 and interim CEO from January to July, 2020.
Dr. Rieders is a Founding Director of the Fredric Rieders Family Foundation where he served as Chairman, Secretary and Chief Science Officer at various times during his over 25 years of active leadership on the Board of Directors. He was Program Director of Forensic Toxicology for the Foundation’s MSFS Program which he helped to create at Arcadia University. Dr. Rieders continued as volunteer faculty at Arcadia University and in Foundation internship programs providing lectures and seminars including an introduction to cold case forensics where Masters students participated in a cold case review at the Vidocq Society of Philadelphia.
Dr. Rieders is a supporter and guest speaker at the Forensic Sciences Mentoring Institute and worked on the African Wildlife Poisoning Program which he continues to sponsor. He lead the development of the now ongoing International Toxic Adulterants Data Base Program.
Dr. Rieders is a Fellow of The American Academy of Forensic Sciences (AAFS) where he was Chairman of the AAFS Opioids and Emerging Drugs Crisis Committee from 2017 – 2019. He remains active as Chair of the Information Sharing Sub-Committee and as a member of the Toxicology Section.
Dr. Rieders is a Member of the American Public Health Association (APHA) where he has interest in substance use dependence in pregnant women, opioids and emerging drugs, chemical exposure biomonitoring and toxic adulterant cutting agents in street drugs.
Dr. Rieders is a member of the Society of Forensic Toxicologists (SOFT), The International Association of Forensic Toxicologists (IAFT), the World Association of Medical Law (WAML), and The National Association of Medical Examiners (NAME) where he serves on their Strategic Planning Committee, Workforce Development Subcommittee, Forensic Toxicology Committee, Government Affairs Committee and NAME Foundation Board of Trustees.
He served on Pennsylvania’s Commission on Wrongful Convictions where he worked with the Forensic Science Subcommittee on recommendations to improve the forensic science investigation system. Dr. Rieders has qualified as an Expert in Forensic Toxicology and testified in numerous criminal, civil and arbitration proceedings.
Dr. Rieders earned a Chemistry degree from Arcadia University (formerly Beaver College) in 1980, and a PhD in Pharmacology/Toxicology from Thomas Jefferson University in 1985 where he was active as volunteer faculty and lectured in Toxicology. He is past President of the Jefferson College of Graduate Studies Alumni Association where he was honored as Distinguished Alumnus. Dr. Michael F. Rieders was the 2015 honoree of the Jefferson President's Award which is given to Jefferson’s strongest supporters. He continues to serve on Jefferson's Institutional Advancement Board. Dr. Michael F. Rieders and members of the Rieders Family were recognized with Jefferson's Leader of Innovation Medal in May of 2021.
Dr. Rieders served as a Term Trustee on the Arcadia University Board from 2009 - 2012, and as a volunteer faculty member serving as a course director and lecturer in Toxicology at Arcadia’s Master of Forensic Sciences Program. He serves as Chairman of the Board of Advisors and Fellows at The Henry C. Lee Institute of Forensic Sciences at New Haven University. Dr. Rieders is Chief Science Officer of The Vidocq Society, the premier US cold murder case investigation organization which examines cases and assists law enforcement agencies in identifying leads that may help solve homicides. He was awarded the Dr. Halbert E. Fillinger, Jr. Medal and Lifetime Achievement Award by The Vidocq Society in 2013. Dr. Rieders previously served on the Society's Board of Directors.
Dr. Rieders was an editor of the Pennsylvania Academy of Sciences publication Science Technology and National Security, and wrote a chapter in Forensic Aspects of Chemical Terrorism and recently published an article on his work with NASA: “Management of a Potentially Toxic Accidental Trialkylamine Ingestion during Spaceflight” in Aviation, Space and Environmental Medicine.
Dr. Rieders was featured as a Forensic Scientist in the BBC film, “How Sherlock Holmes Changed the World of Forensic Science” and Smithsonian Channel’s “Forensic Firsts: Proving Poison”. He is a frequent guest speaker and presenter at numerous conferences and seminars.
Dr. Rieders is an avid advanced open water scuba diver, a sushi chef and enjoys gardening, photography and international travel.
Eric F. Rieders
Corporate Secretary, Board of Directors
Dr. Rieders earned a Doctorate in Mathematics from Syracuse University and a BS in Chemistry and Mathematics from Ripon College (Ripon, WI). He is also the Chairman of the Board of the Fredric Rieders Family Renaissance Foundation and an adjunct Professor of Forensic Science at Arcadia University.
Marian (Mim) Rieders
Director, Board of Directors
Marian was responsible for managing the financial operations of the company working closely with our accounting firm representative, Andrew Nolan, who is VP of Finance. Marian Rieders has been a Board member since 1990 serving as a Corporate Officer in the position of Treasurer and Secretary to the corporation.
Director, Board of Directors
Frank McCaney is the Chairman of the Board of Directors at NMS Labs. He is an accomplished executive with more than 25 years of demonstrated growth and success in medical devices and drug development. Experienced in Business Management at the CEO level, drug development, raising capital, M&A, Sales and Marketing, and turnarounds. Mr. McCaney previously served as CEO of Strata Skin Sciences (SSKN: NASDAQ) and before that he was CEO of Corpak MedSystems, a private equity-backed medical device company in the field of enteral feeding. Corpak was sold to Halyard Health (HYH: NYSE) for $174 million in May 2016. Prior to Corpak, he was the founder and CEO of Nitric BioTherapeutics, a venture backed-medical technology company from 2006 until 2012. Prior to Nitric Bio, he was a senior executive at Viasys Healthcare, Inc. (VAS: NYSE), a medical technology company focusing on respiratory, neurology, medical disposable and orthopedic products and had a lead role in spinning Viasys out of Thermo Electron Corporation (TMO: NYSE). While at Viasys, Mr. McCaney had several responsibilities including strategy, business development and investor relations. He currently serves as a director of Diasome Pharmaceuticals, a privately-held company. Frank is also the Chairman of the Board of Allevi Inc, a Tissue Bioprinting company located in Philadelphia.
Pierre G. Cassigneul
Director, Board of Directors
Mr. Cassigneul has over 30 years’ experience leading organizations and high-growth-potential start-ups through the development and launch of innovative tests and high-science clinical diagnostic solutions. He has led NMS labs as President and CEO for 6 years before retiring in Dec 2019. Previously, he was with Predictive Biosciences as President and CEO. Mr. Cassigneul was born in France where he graduated from Reims Management School.
Director, Board of Directors
Nicholas F. Rieders, BSRN, CCTM has been employed as a registered nurse at Jefferson University Hospital for 6 years in the Intermediate Neurological Intensive Care and Comprehensive Spine Units. Nicholas earned a Bachelor of Science in Kinesiology from Temple University and went on to complete an accelerated bachelors degree in Nursing at Villanova University where he was inducted into the nursing honors society, Sigma Theta Tau.
Nicholas is passionate about making a difference through compassionate and individualized care and continues to seek out new learning and leadership opportunities.
Nicholas has served on the Board of Directors for the Fredric Rieders Family Renaissance Foundation and is honored to join the Board of Directors of NMS Labs to continue the legacy of Dr. Fredric Rieders.
Director, Board of Directors
Cornelius P. McCarthy is a founding partner and Managing Director of Fairmount Partners, a Philadelphia based investment bank. Neal focuses primarily on the healthcare and laboratory sciences sectors, and has assisted clients to complete financings, acquisitions, mergers and divestitures throughout North and South America, Europe, Asia and Australia. Prior to founding the Company, Neal was the US Head of Corporate Finance and Head of Healthcare Investment Banking at Investec, Inc., an international banking group based in the UK.
Before joining Investec, Neal worked for investment banks in New York and Los Angeles where he specialized in mergers and acquisitions and public offerings of equity and debt. He has significant experience in healthcare, cable and telecommunications, insurance, manufacturing, and transportation. Before that he practiced securities and general corporate law for the firm of Gibbons PC.
He previously served on the Board of Phoenix International Life Sciences, a large public pharmaceutical research and labs business, and the Board of Medpace Inc. a top 10 clinical CRO, assisting both with strategy and acquisitions. He is a member of the Drug Information Association and the American Association of Pharmaceutical Scientists.
Neal received his legal degree from Villanova University School of Law and earned his undergraduate degree from the University of Virginia, where he was an Echols Scholar.
President and Chief Executive Officer, Director, Board of Directors
Daniel Monahan is President and Chief Executive Officer at NMS Labs. He is also a Director on the Board of Directors.
He is responsible for leading the strategic growth and expansion of NMS Labs as we pursue the company’s broader purpose of advancing public health and public safety.
Dan has extensive experience in leadership positions during his 9 years with Thermo Fisher Scientific. Most recently he was Vice President and General Manager within Unity Lab Services. Prior to that role, Mr. Monahan was the Vice President and General Manager of a $1B global distribution business. Earlier in his career, he held positions in various functional areas including commercial operations, marketing, business development, finance, and product development.
Dan holds an MBA with distinction from Harvard Business School, and a Master of Engineering and Bachelor of Science in Chemical Engineering from Illinois Institute of Technology.
David Delia is Chief Financial Officer at NMS Labs. David is responsible for NMS Labs’ financial management and information technology, including business planning and program management. Additionally, he oversees the facilities and purchasing for the company and is a member of the executive management team.
David has extensive operational and financial experience in healthcare and was named Chief Financial Officer in 2016 after serving as Senior Vice President of Operations at Alliance Health Care Services for 4 years. Prior to that, David spent 12 years in financial and operations roles at LabCorp, the largest clinical laboratory in the United States.
David holds a Master of Business Administration from the University of South Florida and a Bachelor of Science from East Carolina University.
Marianne Jackson is the Senior Vice President and General Manager for the Clinical Business Unit at NMS Labs. She joined the company in April of 2021 and is responsible for overseeing the strategic growth and expansion of the clinical business.
Marianne has an extensive commercial background with over 25 years of experience with life science companies. She has worked in large, mid-size and start-up biopharma companies, building and leading functional areas in marketing, market access, sales and commercial operations. Most recently, Marianne worked as the Senior Vice President of Sales and Market Access at Synergy Pharmaceuticals. Prior to that she served as the SVP of Global Commercial Operations at Shire, helping transform the organization into a rare disease company that was acquired by Takeda. Earlier in her career Marianne worked in a variety of commercial roles in AstraZeneca and Merck.
Marianne holds a Master of Science and Bachelor of Business Administration from Texas A&M University.
Daniel Reed is the Senior Vice President and General Manager for the Forensic Business Unit at NMS Labs. Dan joined the team in August of 2021, and is responsible for overseeing the strategic growth and expansion of the forensic business.
With over a decade of experience in market intelligence and research, strategy, portfolio management, pricing, and supply chain, Dan has led teams focused on order management, contract management, and sales CRM and quoting tools. Most recently, he served as the Senior Director of Global Commercial Operations for the Chromatography and Mass Spectrometry Division of Thermo Fisher. Additionally, Dan was previously an economist at the Bureau of Economic Analysis.
Dan holds a Masters in Business Administration with Distinction from the Tuck School of Business at Dartmouth and a Bachelor of Arts in Economics and History from the University of Virginia.
Barry K. Logan
Dr. Barry Logan is Sr. V/P of Forensic Sciences, and Chief Scientist at NMS Labs. He joined NMS Labs in 2008. He is also Executive Director at the non-profit Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation in Willow Grove, Pennsylvania. At NMS Labs he leads our team of forensic toxicologists and certifying scientists and is the laboratory director for NMS Criminalistics Laboratories in Pennsylvania, Texas and North Carolina.
Dr. Logan is a Fellow of the American Board of Forensic Toxicologists (ABFT), and has over 150 publications and over 600 presentations in forensic toxicology and analytical chemistry, including work on the effects of illicit and prescription drugs on drivers, and drug caused and related death. His current research priorities are focused on new drug trends, the opioid crisis, rapid reporting of drug mortality data, and the analytical and interpretive toxicology and chemistry of novel psychoactive substances, founding www.NPSDiscovery.org in 2018.
Dr. Logan’s other appointments include Executive Director of the Robert F. Borkenstein course at Indiana University, and at Arcadia University and Thomas Jefferson University in Philadelphia. He serves on the Advisory Board for NIDA’s National Drug Early Warning System (NDEWS). In recognition of his work and contributions, Dr. Logan has received numerous national and international awards, and served as President of the American Academy of Forensic Sciences (AAFS) in 2013-14.
Robert A. Middleberg
Dr. Robert A. Middleberg is the Core Laboratory Director and Sr. Vice President of Quality Assurance and Regulatory Affairs at NMS Labs. He earned his Ph.D. in Pharmacology from Thomas Jefferson University and a Master’s Degree in Chemistry from the University of Pittsburgh. He is a Fellow of the American Board of Forensic Toxicology (F-ABFT) and a Diplomate in Toxicological Chemistry from the American Board of Clinical Chemistry (DABCC-TC). Dr. Middleberg is a faculty member at Thomas Jefferson University. He holds a position on the Board of Directors for the American Board of Forensic Toxicology and served previously as a Director on the American Board of Clinical Chemistry. Dr. Middleberg was awarded the Rolla N. Harger award in 2013 for contributions to forensic toxicology by the Toxicology Section of the American Academy of Forensic Sciences. He is a member of many professional organizations, including the American Academy of Forensic Sciences, the American Association for Clinical Chemistry and the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Dr. Middleberg was a long-standing member of the College of American Pathologists’ Toxicology Committee and now serves as an advisor and currently sits on the Editorial Board for the Journal of Forensic Sciences.
Jennifer Charlton is the Senior Vice President of Human Resources at NMS Labs. She joined the company in December 2019 and is responsible for leading employee engagement, compensation and benefits, talent acquisition, training and development, HR operations and employee relations. Additionally, Jen is a member of the executive management team.
Jen has extensive HR and business support experience in the banking and transportation industries. She spent 23 years at Bank of America in senior HR roles supporting global wealth and retirement, commercial real estate and credit card businesses, and most recently spent 5 years in a senior HR role supporting the Commercial Executive, Chief Marketing Officer and Chief Financial Officer of Amtrak.
Jen holds a Master of Business Administration and a Bachelor of Science from the University of Delaware.
Keith Hoerth is the Vice President of Laboratory Operations at NMS Labs. He is responsible for the Core Laboratory Operations of NMS Labs with a focus on meeting the expectations of the clients, goals of the organization, and stringent national accreditation requirements.
Keith has nearly 20 years of laboratory experience starting as a laboratory scientist and continuing to progress in his career. Most recently he was Vice President of Laboratory Services at Kaleida Health, a large health care system in Buffalo, NY. Prior to that role, Mr. Hoerth was the Director of Laboratory Services for SwedishAmerican Health system, part of UW Health, in Rockford, IL. He has been a lead inspector for the College of American Pathologists, and American Association of Blood Banks assessment teams with a focus on driving continual quality and process improvement.
Keith obtained his Fellowship in the American College of Healthcare Executives, holds an MHA from the University of Phoenix, Bachelor of Science in Clinical Laboratory Science from the University of Wisconsin, and is a certified Medical Laboratory Scientist.